ENTEROME TRANSLATE MOLECULAR UNDERSTANDING OF THE ROLE OF THE HUMAN GUT MICROBIOME TO DELIVER INNOVATIVE PERSONALIZED MEDICINE AND IMPROVE PATIENT HEALTH.

Gut microbiome plays a crucial role in the building-up of our immunity system at birth. It is a life-long personal and natural protection but increasing evidence suggests that dysregulated immune responses against commensal microbes in the gut are strongly involved in Inflammatory Bowel Diseases, Metabolic disorders, Oncology, Depression, Allergies amongst numerous diseases.

Enterome dedicates its activities to the development of innovative therapeutic approaches (drugs and biomarkers) to support a personalized medicine for microbiome-related diseases.

CROHN DISEASE & IBD

Crohn’s disease and other IBD such as Ulcerative Colitis, are chronic inflammatory diseases which affect over 3 million Americans and Europeans, most of whom are generally diagnosed before age 35. These chronic, life-long conditions have a major impact on patient’s quality of life.

Current medical treatment of CD consists of immunosuppressive drug therapy which control symptoms of CD in most patients, but their withdrawal leads to disease relapse and are also associated with serious side effects.

Our approach is based on an oral and non-systemic small molecule drug candidate that is designed to block FimH-mediated attachment of Adherent Invasive E Coli (AIEC) thereby preventing local inflammatory cytokine production and the entry of AIEC into the gut wall by selectively disarming the virulent bacteria without disrupting the gut microbiome.

MORE ABOUT

IMMUNO-ONCOLOGY

Cancer is a disease caused by changes to genes that control the way our cells function, especially how they grow and divide ; and which has a major impact on society across the world.

Rationale behind cancer vaccination lies on delivering tumor antigens to patients and on targeting their dendritic cells, with the aim of inducing an efficient presentation of cancer epitopes to T lymphocytes and, consequently, boost a sustained immune response against cancer cells expressing the same antigens at the tumor site.

Our work on discovering and developing novel bacterial-derived cancer antigens that are expressed in human gut microbiome, and wish to provide new solutions to making cancer cells detectable by adoptive immune system and to boost their immunogenicity.

MORE ABOUT

AUTOIMMUNE DISEASES

Autoimmune diseases develop when the immune system, natural body defense against disease, consider the healthy cells as foreign. Therefore this dysregulation of the immune system attack healthy cells. Autoimmune diseases can affect many different types of body tissue.

They affect at least 5% of the population.

In the absence of curative therapy, treatment for autoimmune diseases focuses only on relieving symptoms.

COLLABORATIONS

In 2016, Enterome has entered with BMS into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer. Additionally, the collaboration will seek to identify novel microbiome-derived biomarkers in an effort to improve clinical outcomes for patients treated with Bristol-Myers Squibb’s Immuno-Oncology portfolio.

The collaboration will combine Bristol-Myers Squibb’s expertise in the discovery and development of novel immunotherapies with Enterome’s proprietary metagenomic technology platform and leadership in the rapidly advancing science of the gut microbiome to support the discovery of novel immunotherapy agents and biomarkers. There is a growing body of scientific evidence to suggest that the gut microbiome plays an important role in modulating mechanisms of response and resistance to cancer immunotherapies. Changes in a host’s immune system driven by the gut microbiome can be exploited to identify specific targets and bioactive compounds with the potential to augment anti-cancer immune responses.

In January 2016, Enterome has announced a collaborative research agreement with Janssen Biotech, Inc. (Janssen Biotech), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the French National Institute for Agriculture Research (INRA).

The agreement, facilitated by Johnson & Johnson Innovation, is focused on the discovery of novel targets and bioactive molecules from the gut microbiome for the potential development of therapeutic solutions to Crohn’s disease.

The collaboration aims to advance the characterization and therapeutic validation of these bacterial products, increase knowledge of the regulation of immunity and gut homeostasis, and potentially lead to the development of new therapeutic solutions for Crohn’s disease.

The Janssen Human Microbiome Institute will also join the collaboration to help accelerate the translation of microbiome science into therapeutic solutions in the area of Crohn’s disease.

In January 2016, Enterome has announced a strategic drug discovery collaboration with Takeda Pharmaceutical, to research and develop potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases (e.g. ulcerative colitis) and motility disorders (e.g. irritable bowel syndrome).

LEADERSHIP

MANAGEMENT
TEAM

PIERRE BELICHARD

pb

VP M&A and business development at Sanofi Ophthalmology, Pierre was the founder and COO of Fovea Pharmaceuticals and has been instrumental in building up the product-portfolio that became the Ophthalmology division of Sanofi (Fovea was acquired by sanofi in 2009 for €370m, less than five years after inception). Earlier, Pierre was VP Business Development at UroGene, a company sold to Pierre Fabre in 2004. In 2000, he took over the position of head of European commercial operations at Ethypharm. Prior to this, Pierre held various positions in science and business development at Fournier Pharma. Pierre is PharmD, PhD and holds a MBA from INSEAD.

CHIEF EXECUTIVE OFFICER

MARIE-LAURE BOUTTIER

mlb

Business Development & Contract Manager at Sanofi, Marie-Laure joined Fovea Pharmaceuticals at inception as Business Development associate and has been involved in all licensing and contractual operations of the company from founding to trade sale to Sanofi. Earlier, Marie-Laure has been Business Development associate at UroGene.

CHIEF OPERATING OFFICER

RODOLPHE CLERVAL

rc

Before joining Enterome, Rodolphe Clerval was VP Corporate and Business Development of TcLand Expression, a molecular diagnostic company. During his tenure with TcLand Expression, he led strategic planning activities and closed several collaborations and licensing deals. Previously he was Business Development Manager at Genzyme. Prior to this he was financial analyst for the brokerage firm Natixis Bleichroeder. Earlier in his career, Rodolphe served as Research Scientist at Aventis Animal Nutrition.

CHIEF BUSINESS OFFICER

JAI PATEL

jp

With over 25 years of global medicine development experience, Jai joined Enterome in August 2016. Most recently Jai served as the Chief Medical Officer at Nephrogenex. Prior to that he held positions of increasing responsibility at GSK, serving as Vice President in Clinical Development, Medical Affairs, Project Management and Global Regulatory Affairs for the Cardiovascular and Metabolism Therapeutic Area. Jai graduated from St. Bartholomew’s Hospital, University of London and completed his post-graduate training at St Bartholomew’s Hospital and Kings College Hospital in London. He is a member of the Royal College of Physicians (UK).

CHIEF MEDICAL OFFICER

CHRISTOPHE BONNY

cb

Christophe has 20 years’ experience in the field of molecular biology and signaling pathways, 15 years in the field of hit identification to candidate selection, has authored 80 scientific publications and is an inventor on 12 patent families. Before joining Enterome, Christophe was CSO at Bicycle Therapeutics. He discovered XG-102/AM-111 and XG-104, the two first clinical stage intracellular peptidic inhibitors of the JNK protein. These compounds, now in clinical phases 2 and 3, formed the basis for the creation of the biotechnology company Xigen SA in 2003. In 2005, he received the Pfizer Research Prize for this discovery. Christophe was CSO of Xigen SA and also served as its President for 6 years.

CHIEF SCIENTIFIC OFFICER

CHRISTELLE DUMOUSSAUD

cd

Christelle joined Enterome in November 2015 with more than 20 years of experience in financial departments of various industries. Lately, she worked in the services industries for public and private companies, focused on structuring the administrative and finance department and on securing the business development. She previously served as Finance Director at Fournier/Solvay Pharma. During these years, she was in charge of cross-functional projects regarding the reorganization of the new pharmaceutical division and acted during 4 years as CFO of the Belgian subsidiary. She has started her career as business analyst for mass market groups like Sara Lee and Diageo. Christelle holds a Master in Business Management from the ISC Paris.

CHIEF FINANCIAL OFFICER

BOARD OF
DIRECTORS

GEORGES GEMAYEL

Georges has over 25 years of experience in the pharmaceutical industry, including management and executive positions in the US, Europe and the Middle East. He currently serves on the board of directors of US publicly-traded companies Supernus Pharmaceuticals, Inc. and Raptor Pharmaceutical Corp., and is the Chairman of the boards of OxThera AB, EpiTherapeutics ApS and Orphazyme ApS. From 2008 to 2009, Dr Gemayel was President and Chief Executive Officer of Altus Pharmaceuticals Inc., a publicly-traded pharmaceutical company. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation where he was responsible for the company’s global therapeutics, transplant, renal and biosurgery businesses. From 1998 to 2003, he held progressively senior roles at Hoffmann La-Roche and Roche Labs, most recently as Vice President, National Specialty Care, responsible for its US business for dermatology, oncology, transplantation, hepatitis and HIV.

CHAIRMAN OF THE BOARD

PIERRE BELICHARD

pb

VP M&A and business development at Sanofi Ophthalmology, Pierre was the founder and COO of Fovea Pharmaceuticals and has been instrumental in building up the product-portfolio that became the Ophthalmology division of Sanofi (Fovea was acquired by sanofi in 2009 for €370m, less than five years after inception). Earlier, Pierre was VP Business Development at UroGene, a company sold to Pierre Fabre in 2004. In 2000, he took over the position of head of European commercial operations at Ethypharm. Prior to this, Pierre held various positions in science and business development at Fournier Pharma. Pierre is PharmD, PhD and holds a MBA from INSEAD.

CHIEF EXECUTIVE OFFICER

PIERRE CASSIGNEUL

Pierre has over 25 years’ experience in leading organizations and high-growth-potential start-ups through the development and launch of innovative tests and high-science clinical diagnostic solution. He is currently President and Chief Executive Officer at NMS Labs. Before this, he was CEO at Molecular Diagnostic LTD, President and CEO, XDX Inc. Earlier, Pierre was VP Diabetes Management, Becton Dickinson, Senior VP Business Operations, Bayer US and BU General Manager, J&J.

INDEPENDENT

JOHAN KÖRDEL

Johan Kördel has served as a member of our board of directors since March 2012. Before joining Lundbeckfonden Ventures in 2010, Johan worked 20 years in the pharma and biotech industry with structural biology, discovery, research management, early development, portfolio management, business development and alliance management. Johan was previously co-founder and CEO of Sound Biotech ApS and co-founder and Senior Vice President of Research as well as Business Development of Biovitrum AB. Prior to these positions he worked almost a decade in the pharmaceutical company Pharmacia. Johan has co-founded other biotech companies and been serving on numerous boards both in private and public life science companies. Johan trained as a Physical Chemist at University of Lund, Sweden, Scripps Research Institute, La Jolla, California and Harvard Medical School, Boston, Massachusetts. He is an associate professor in Physical Chemistry at the University of Lund, Sweden. Johan is a board member of Acacia Pharma, Enterome, Iconic Therapeutics and VHSquared

LUNDBECKFONDEN VENTURES

ISABELLE DE CREMOUX

Isabelle de Cremoux has served as a member of our board of directors since 2008 and is CEO and Managing Partner of Seventure where she leads the Life Sciences team. Isabelle began her career in 1991 with Arthur Andersen in Detroit, USA. She then moved to Pfizer France and Pfizer Europe where she held various positions for six years within management, clinical research and business development. In 1998, Isabelle joined Laboratoire Fournier / Abbott as Deputy Director of Business Development, in charge of product and technology licensing and acquisitions, and signed numerous Europe and and USA deals. She joined Seventure in 2001 to establish the Life Sciences division. Isabelle supervises the Life Sciences business and personally invests in French and Scandinavian biotech, nutrition, healthcare, personalized medicine. Isabelle has a particular interest in the microbiome field. Isabelle’s investment experiences include Santaris (sold to Roche for $450 million in August 2014), ArgenX (listed), OPI (sold to Eusa for € 110 million), Bioalliance (listed), Pixium vision (listed). She is currently responsible for Enterome Biosciences, Maat Pharma, Targedys, LNC, etc. Isabelle holds a degree in Engineering from l’Ecole Centrale Paris and brings more than 25 years of international business development and finance experience in the pharmaceutical industry to the team.

SEVENTURE PARTNERS

FELIX FRUEH

Felix is a respected thought leader in personalized medicine with nearly twenty years of R&D, management and policy experience. He is currently CEO at Intellos Health. Felix previously holds the CSO position at Human Longevity Inc. He was also Manager in residence at Third Rock and President, Medco Research Institute at Medco Health Solutions, Inc. (now Express Scripts). Earlier, Felix was Associate Director for Genomics at FDA/CDER/Office of Clinical Pharmacology (OCP) and Research Director, Pharmacogenetics at Transgenomic.

INDEPENDENT

ROGER GARCEAU

Roger is Board certified pediatrician with 30 years Pharmaceutical Development, Global Regulatory and Medical Affairs experience. Experience in multiple successful FDA Advisory Committee meetings, EU Scientific advice and PDMA meetings. Roger has a broad experience in drugs, biologics and combination drug/device products for orphan and non-orphan indications, both in US and Internationally. Roger successfully built development and medical organizations from ground up. Roger recently led two successful orphan products through filing, Advisory Committees and registrations.

INDEPENDENT

MARY THISTLE

mt

Mary brings extensive experience in the life sciences industry, serving in senior finance, operations and business development roles. She is currently Chief Operating Officer at Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus (AAV) gene delivery technology.Prior to joining Dimension in 2015, Ms. Thistle was Senior Vice President, Business Development at Cubist Pharmaceuticals, where she was responsible for four major acquisitions, including Trius Therapeutics and Optimer Pharmaceuticals, significantly driving growth of the company’s pipeline prior to Cubist’s $9.5 billion acquisition by Merck & Co. (MSD outside the US). Prior to this, she held leadership positions at ViaCell, Inc. Ms. Thistle began her career in finance as a certified public accountant working with both private and public companies. She received her B.A. degree in accounting from the University of Massachusetts.

INDEPENDENT

BRUNO MONTANARI

OBSERVER OMNES CAPITAL

CATHY KERZNER

OBSERVER NESTLÉ HEALTH SCIENCE CAPITAL

REJANE LE TINEVEZ

Bio en cours

OBSERVER INRA

TECHNOLOGY

Two complementary metagenomic platforms
for a full genomic and functional analysis of the microbiome

A QUANTITATIVE METAGENOMICS PLATFORM

based on full sequencing and mapping of total fecal bacterial gene content that allows the characterization of a personal metagenome (metagenotype®) associated with a disease phenotype. This technology enables the identification of biomarkers and of bacteria of interest associated with the development of diseases.

A FUNCTIONAL METAGENOMICS PLATFORM

based on the screening of genomic or metagenomics libraries on cell based assays and on specific pathways of interest that allows the discovery and the development of news drugs and targets.

PORTFOLIO

ENTEROME-Approche-globale-V4

PROGRAMS & PRODUCTS

CROHN DISEASE & IBD

EB8018

EB8018 is an oral and non-systemic small molecule drug that is designed to block FimH-mediated attachment of Adherent Invasive E Coli (AIEC) thereby preventing local inflammatory cytokine production and the entry of AIEC into the gut wall by selectively disarming the virulent bacteria without disrupting the gut microbiome.

MORE ABOUT

Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract. Emerging evidence suggests that the microbiome plays an important role in triggering an abnormal mucosal immune response in patients with Crohn’s disease. Enterome has identified the FimH adhesin from overabundant E. coli species as a potential novel target to block inflammation in Crohn’s disease (CD) through application of its metagenomics platform to the microbiomes of patients suffering from Crohn’s disease. Independent studies have also demonstrated an imbalance of the microbiomes of such patients with a significant increase of E. coli with invasive properties, termed adherent-invasive E. coli (AIEC). These AIEC bacteria attach to the gut wall of susceptible patients via the fimbrial adhesion protein FimH, and subsequently trigger inflammation by inducing local production of cytokines and invasion of the gut wall through activation of TLR4 and CEACAM6 receptors which are strongly upregulated in the ileum of Crohn’s disease patients. EB8018 is an oral and non-systemic small molecule drug that is designed to block FimH thereby preventing local cytokine production and the entry of AIEC into the gut wall by selectively disarming the virulent bacteria without disrupting the gut microbiome. It represents a novel, non-biologic, non-steroidal, non-antibiotic, non-immunomodulatory and local approach for the treatment of Crohn’s disease. Enterome in-licensed EB8018 from Vertex Pharmaceuticals Inc. EB8018 is currently being tested in a Phase 1 clinical study is designed to determine the safety and tolerability profile of single and multiple doses of EB8018 in healthy subjects. The study will also assess the pharmacokinetic profile of single and multiple doses of EB8018 and the effects of EB8018 on the healthy gut microbiome. In parallel with the phase 1 study, Enterome is currently investigating prevalence of FimH expressing bacteria in the ileum of CD patients.

EB410/EB420

EB410 & EB420 are both therapeutic programs for the discovery of new drug candidates for the treatment of Inflammatory Bowel Diseases. Enterome and Takeda Pharmaceutical jointly collaborate for the development of new drug candidates for the treatment of severe GI disorders.

EB110/EB220

EB110 & EB220 are both therapeutic programs for the discovery of new drug candidates in Crohn Disease. Enterome and Johnson & Johnson jointly collaborate for the discovery of novel target and microbiome derived bioactive molecules.

IBD110

IBD110 is a diagnostic based on the measurement of the inflammatory activity. IBD110 aims to assess and control disease progression.

IBD210

IBD210 is a companion diagnostic related to EB8018, Enterome clinical stage drug candidate in Crohn disease. IBD210 enables to quantify FimH protein expression in fecal samples from patients.

IMMUNO-ONCOLOGY

EO2315

Enterome is discovering and developing novel microbiome-derived cancer vaccines in order to make cancer cells detectable by adoptive immune system and to boost immunogenicity. EO2315, the front-runner candidate of this program is currently in non-clinical development to treat patients with Glioblastoma Multiforme (GBM).

MORE ABOUT

Vaccination is a very promising immunotherapeutic approach to advancing toward a cure for cancer. The rationale behind cancer vaccination lies on delivering tumor antigens to patients and on targeting their Dendritic Cells (DC) to allow efficient presentation of cancer epitopes to T lymphocytes and, consequently, to induce a sustained immune response against cancer cells expressing the same antigens at the tumor site. Enterome is discovering and developing novel bacterial-derived cancer antigens derived from known tumor antigens in order to make cancer cells detectable by the adoptive immune system and boost immunogenicity, resulting in an expected improvement in clinical outcomes. Based on the concept of molecular mimicry between bacterial and cancer epitopes, bacterial-derived antigens expressed in human gut microbiome are confronted using alignment tools with human tumor antigen-derived peptides. 100+ bacterial-derived peptides have been identified through their high MHC affinity and are being investigated. The front-runner of this program is EO2315 and is currently in non-clinical development for treatment of Glioblastoma Multiforme (GBM), a highly aggressive solid neoplasm that is the most lethal form of brain tumor.

EO520

EO520 is a therapeutic program for the discovery of new drug candidates for the treatment of cancer. Enterome and Bristol-Myers Squibb jointly collaborate for the discovery of novel biomarkers.

bms2

EO510

EO510, is a therapeutic program for the discovery of new drug candidates for the treatment of divers types of cancer such as glioblastoma, colon, pancreatic, lung and breast. This therapeutic program enables Enterome to discover microbiome related neoantigens.

IOC520

IOC520 is a companion diagnostic related to a BMS immuno-oncolgy commercialized drug. In collaboration with BMS, Enterome develops this diagnostic which aims to highlight the role of a healthy gut microbiome in the efficacy of a lung cancer treatment.

SCIENCE
PIPELINE

INVESTORS

Our company has been established in 2012 and has already raised a €32m in three rounds with private equity funds (Seventure, Omnes Capital, Lundbeckfonden, Health for Life Capital) and strategic investors (INRA Transfert, Shire & Nestlé).

MORE ABOUT

Being one of the leading venture capital firms in Europe, Seventure manages €500m and invests since 1997 in innovative businesses with high growth potential in IT and in Life Sciences. With preferred sectors of Biotech & Pharmaceuticals, Medtech, Industrial Biotech & Cleantech, and Lifestyle Healthcare & Nutrition. Seventure is a subsidiary of Natixis.

MORE ABOUT

Lundbeckfonden Ventures is a life science venture fund established in 2009 and wholly owned by the Lundbeck Foundation. On an annual basis, Lundbeckfonden Ventures invests up to € 50 million. Investments are made within lifescience, focusing on pharmaceuticals and biopharmaceuticals, medtech, diagnostics and healthcare service companies.

MORE ABOUT

Omnes Capital is a major player in private equity, with a commitment to financing SMEs. With €2.1 billion in assets under management, Omnes Capital provides companies with the capital needed to finance their growth. Omnes Capital, formerly Crédit Agricole Private Equity, was a subsidiary of Crédit Agricole until March 2012 when the company was acquired by Coller Capital.

MORE ABOUT

Nestlé Health Science, a wholly-owned subsidiary of Nestlé, is a health-science company engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and its partners in healthcare. Nestlé Health Science’s portfolio of nutrition solutions, diagnostics, devices and drugs targets a number of health areas, such as inborn errors of metabolism, pediatric and acute care, obesity care, healthy aging as well as gastrointestinal and brain health. Through investing in innovation and leveraging leading edge science, Nestlé Health Science brings forward innovative nutritional therapies with clinical, health economic value and quality of life benefits. Nestlé Health Science employs around 3,000 people worldwide. For more information, please visit: www.nestlehealthscience.com.

MORE ABOUT

Shire is a pharmaceutical company formed 25 years ago and focusing on developing treatments for conditions in a large range of domains like CNS, Gastrointestinal, Orphan genetic diseases, Allergy and Hematology. In 2011, the company’s revenue was USD 4.3 billion. Shire has committed initial capital funding of $50 million to establish a Strategic Investment Group. Shire co-invests via the SIG as part of a syndicate.

MORE ABOUT

Health for Life Capital supports innovative high-growth entrepreneurial ventures. Geographically, its focus is primarily in Europe, but also extends to North America and Asia. Investments will be made in the areas of healthcare, life sciences, biotechnology, medical technologies, pharmaceuticals, nutrition and in the emerging fields of microbiome and connected health.

MORE ABOUT

INRA Transfert is a project engineering company and technology transfer for food innovation, agriculture and environment that promotes and manages the INRA technology portfolio through operating agreements with industry and supports the development of young innovative companies.

PRESS, NEWS & EVENTS
PRESS RELEASES
2017
12Jul

Enterome appoints Mary Thistle to its Board of Directors

Paris, France – July 12, 2017 Enterome SA, a pioneer of innovative therapies for microbiome-related diseases, is pleased to announce that Mary Thistle has joined the Read More →
11Jul

Enterome and Nestlé Health Sciences launch new diagnostics company

Microbiome Diagnostics Partners (MDP) to focus on the development of novel microbiome-based diagnostics for IBD and liver diseases Paris, France – July 11, 2017 Enterome Read More →
05Jan

Enterome starts Phase I clinical trial with its lead candidate EB8018 to treat Crohn’s disease

EB8018 is a first-in-class oral small molecule targeting the host-microbiome interaction by blocking FimH Paris, France and Cambridge, MA, USA – January 5, 2017 Enterome Read More →
2016
09Dec

Enterome further strengthens its leadership team and Board adding clinical development experience

Jai Patel appointed as Chief Medical Officer and Roger J. Garceau elected to the Board New York and Paris, December 9, 2016 Enterome SA a Read More →
16Nov

Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules

New York and Paris, November 16, 2016 Bristol-Myers Squibb (NYSE: BMY) and Enterome SA (Enterome), a pioneer in the development of pharmaceuticals and diagnostics based Read More →
MORE PRESS RELEASES
NEWS & EVENTS
12Sep

NLS Days 2017

12-14 September 2017 - Malmö (Sweden) Read More →
21Sep

Microbiome Summit’17

Translating into diagnostics and biotherapeutics / 21-22 September 2017 - Vienne (Austria) / Read More →
24Sep

SPS Annual Meeting

24-27 September 2017 - Berlin (Germany) Read More →
25Sep

Discovery on Target

25-29 September 2017 - Boston (USA) Read More →
25Sep

Bio Pharm America

25-27 September 2017 - Boston (USA) Read More →
MORE NEWS & EVENTS

ENTEROME IS LOOKING FOR NEW TALENTS
IN BIOINFORMATICS, CLINICS AND PROJECT MANAGEMENT.

POSTE – Technicien de laboratoire (H/F)

Technicien de laboratoire (H/F) – Statut Employé Type d’offre : Offre d’emploi Contrat : CDI Lieu de travail : Genopole (Evry) Spécialité : Read More →

POSTE – Technicien de laboratoire (H/F)

Technicien de laboratoire (H/F) – Statut Employé Type d’offre : Offre d’emploi Contrat : CDD de 6 mois renouvelable Lieu de travail : Read More →

JOB OFFER – Data Manager Senior (H/F)

Data Manager Senior (H/F) Contact : info@enterome.com > JOB DESCRIPTION (. pdf / french) Read More →

CONTACT US

info@enterome.com / + 33 (0)1 75 77 27 85

ENTEROME FRANCE

Headquarters

94/96 avenue Ledru-Rollin 75011 Paris – France

Tel : +33 (0)1 75 77 27 85
Email : info@enterome.com

Lab facilities

Biocluster Genopole – 5 rue Henri Desbruères – 91030 Evry Cedex

ENTEROME USA

Subsidiary

One Broadway, 14th Floor, Cambridge MA 02142, USA

Email : info@enterome.com

CONTACT US

Your Name (required)

Your Email (required)

Subject

Your Message